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Abstract
Background: Acute coronary syndrome (ACS) patients are at very high cardiovascular risk and tend to have
recurrent cardiovascular events. The clinical indicators for subsequent cardiovascular events are limited and need
further investigation. This study aimed to explore clinical indicators that were associated with recurrent
cardiovascular events following index hospitalization.
Methods: The data of patients hospitalized with ACS at a tertiary care hospital in northern Thailand between
January 2009 and December 2012 were retrospectively reviewed from medical charts and the electronic hospital
database. The patients were classified into three groups based on the frequency of recurrent cardiovascular events
(nonfatal ACS, nonfatal stroke, or all-cause death) they suffered: no recurrent events (0), single recurrent event (1),
and multiple recurrent events (≥2). Ordinal logistic regression was performed to explore the clinical indicators for
recurrent cardiovascular events.
Results: A total of 405 patients were included; 60 % were male; the average age was 64.9 ± 11.5 years; 40 %
underwent coronary revascularization during admission. Overall, 359 (88.6 %) had no recurrent events, 36 (8.9 %)
had a single recurrent event, and 10 (2.5 %) had multiple recurrent events. The significant clinical indicators
associated with recurrent cardiovascular events were achieving an LDL-C goal of < 70 mg/dL (Adjusted OR = 0.43;
95 % CI = 0.27–0.69, p-value < 0.001), undergoing revascularization during admission (Adjusted OR = 0.44; 95 %
CI = 0.24–0.81, p-value = 0.009), being male (Adjusted OR = 1.85; 95 % CI = 1.29–2.66, p-value = 0.001), and decrease
estimated glomerular filtration rate (Adjusted OR = 2.46; 95 % CI = 2.21–2.75, p-value < 0.001).
Conclusion: The routine clinical practice indicators assessed in ACS patients that were associated with recurrent
cardiovascular events were that achieving the LDL-C goal and revascularization are protective factors, while being
male and having decreased estimated glomerular filtration rate are risk factors for recurrent cardiovascular events.
These clinical indicators should be used for routinely monitoring patients to prevent recurrent cardiovascular events
in ACS patients.
Keywords: Subsequent cardiovascular events, LDL-C < 70 mg/dL, LDL-C goal, Multiple recurrent cardiovascular
events, Acute coronary syndrome, eGFR, Revascularization
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Background
Acute coronary syndrome (ACS) is one of the clinical
manifestations of cardiovascular diseases considered to
be life threatening [1]. Comparing with the Global Regis-
try of Acute Coronary Events (GRACE) [2] that showed
an in-hospital mortality rate of 4.6 %; the in-hospital
death rate was higher in the first [3] and second [4] Thai
registries of ACS patients. Both are multi-center, pro-
spective, nation-wide registries that collect relevant in-
formation in Thailand. The first Thai Acute Coronary
Syndrome (TACS) registry [3] conducted between 2002
and 2004 in 17 provinces showed an in-hospital mortal-
ity rate of 12.6 %. Later, between 2007 and 2008, the sec-
ond registry (the Thai Registry of Acute Coronary
Syndrome, TRACS) was conducted in 39 provinces; it
showed a reduced in-hospital morality of 4.8 %, but the
mortality rates at 6-months and 1-year were still high
(14.1 % and 17.7 %, respectively) [4].
Patients with established cardiovascular disease such
as ACS patients are at higher risk for recurrent cardio-
vascular events following the first event [5–7], with
about 1 % (140/13,608) [6] to 9 % (380/4,162) [7] of
ACS patients having subsequent cardiovascular events.
The first event of the composite of cardiovascular
events was widely used in efficacy analyses for the
Randomized Controlled Trials (RCTs) [8, 9], but the
subsequent events following the first event are gener-
ally not considered in a primary end point analysis.
However, in routine clinical practice both the patients
and physicians are concerned not only about the first
event but also about subsequent events. ACS patients
with different frequency of recurrent cardiovascular
events following their index hospitalization may differ
in their clinical indicators. Investigating recurrent
events, rather than only the first event, can provide
more evidence for physicians and patients on how best
to monitor patients’ progress. Some predictors of sub-
sequent cardiovascular events such as age, high serum
creatinine, and low high-density lipoprotein choles-
terol were reported in survivors of first hospitalized
myocardial infarction [10].
There are limited data available about the clinical indi-
cators for recurrent cardiovascular events in Thailand.
This study aims to explore if any of the information that
is collected as part of routine clinical practice is associ-
ated with recurrent cardiovascular events in patients
with ACS in Thailand.
Methods
Setting and study population
The study setting was the Maharaj Nakorn Chiang Mai
Hospital, which is part of Chiang Mai University, with
1,400 patient beds to serve 1,300,000 outpatients and
48,000 inpatients annually [11]. This tertiary teaching
hospital provides services to patients from Chiang Mai
province (a population of approximately 1,600,000) and
from 17 other provinces in northern Thailand that refer
patients with complicated conditions such as ACS for
specialist treatment. The hospital provides services in
every medical discipline through a number of centers
including the Northern Thailand Heart Center, the
Northern Neuroscience Center, the Trauma Center, the
Cancer Treatment and Research Center, the Respiratory
Research Center, and the Lung Health Center. The re-
search protocol was reviewed and approved by the Re-
search Ethics Committee, Faculty of Medicine, Chiang
Mai University, prior to commencement of data collec-
tion for the study.
We included all patients diagnosed with ACS - includ-
ing unstable angina (UA), non-ST segment elevation
myocardial infarction (NSTEMI), and ST segment eleva-
tion myocardial infarction (STEMI) - aged 18 years and
over, treated with statins, and were admitted to the hos-
pital between January 2009 and December 2012. A diag-
nosis of ACS was based on an ICD-10 (International
Classification of Diseases, 10th Revision) code of I20 (an-
gina pectoris) or I21 (acute myocardial infarction). We
retrospectively reviewed and retrieved the information
for the clinical indicators of interest and cardiovascular
events of the included patients from medical charts and
from the electronic hospital database.
Clinical indicators of interest
Clinical indicators of interest based on routinely clinical
practice were collected: demographic data, co-morbidities,
atherosclerotic risk factors, current medications, and la-
boratory results including lipid profiles (total cholesterol,
low-density lipoprotein (LDL-C), high-density lipoprotein
(HDL-C), and triglycerides), alanine aminotransferase
(ALT), fasting blood glucose, and serum creatinine. The
degree of renal function of patients was classified accord-
ing to the estimated glomerular filtration rate (eGFR) dur-
ing admission with the use of CKD-EPI Creatinine 2009
Equation, which estimated eGFR from serum creatinine,
age, sex, and race, into two groups: < 60 mL/min/1.73 m2
and ≥ 60 mL/min/1.73 m2 [12]. LDL-C goal attainment
was determined at the first follow-up visit of patients
which occurred between 2 weeks and 1 year from the ad-
mission date. LDL-C levels were categorized into one of
three groups: LDL-C < 70 mg/dL, 70–99 mg/dL, and ≥
100 mg/dL; LDL-C < 70 mg/dL (<1.8 mmol/L) was classi-
fied as achieving the LDL-C goal according to the guide-
lines [13]; LDL-C ≥ 100 mg/dL was used as the reference
group in the analysis. Revascularization was defined as
undergoing percutaneous coronary intervention (PCI) or
coronary artery bypass surgery (CABG) during admission
of patients.
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Recurrent cardiovascular events
In our study, recurrent cardiovascular events were de-
fined as nonfatal ACS (myocardial infarction (MI) or un-
stable angina), nonfatal stroke, or all-cause death
following the index hospitalization. Patients were catego-
rized into three groups based on the frequency of recur-
rent cardiovascular events: no recurrent event (0), single
recurrent event (1), and multiple recurrent events (≥2,
Fig. 1). For example, if a patient experienced only a non-
fatal MI, this was classified as having a single recurrent
event. If a patient had a nonfatal MI, and the same pa-
tient subsequently had a stroke, the patient was charac-
terized as having multiple recurrent events. Using this
method, all events were weighted equally (i.e. death and
recurrent MI or stroke were weighted equally).
Statistical analysis
Descriptive statistics were examined to describe variables
with counts and percentages reporting for categorical
variables, and means with standard deviations for con-
tinuous variables. We used nonparametric tests for trends
across ordered groups to investigate differences across
the three groups of patients. Due to the ordinal nature
of the outcome variable (0, 1, ≥2 recurrent events), we
used ordinal logistic regression [14, 15]. Univariable and
multivariable ordinal logistic regression (clustered with
stratum of ACS [UA, NSTEMI, STEMI] and adjusted
with the length of follow-up time) were performed to ex-
plore the clinical indicators for recurrent cardiovascular
events. The two-tailed test was used and p-value < 0.05
was considered statistically significant. All analyses were
carried out using STATA software, version 12 (StataCorp
LP, College Station, TX, USA).
Results
A total of 1,089 medical records of patients diagnosed
with ACS were reviewed. Due to the incompleteness of
the essential data for analysis, lack of LDL-C level at
baseline and follow-up, we excluded 684 patients’ re-
cords, resulting in 405 patients being included in the
final analysis. We performed a comparison analysis be-
tween those patients excluded and included in the analysis
and found that the two groups were not significantly dif-
ferent in their baseline characteristics; but the excluded
patients were older than the included patients (67.2 ± 12.9
vs 64.9 ± 11.5; p-value = 0.003).
In our study, the median time of follow-up from index
hospitalization to the last medical contact, or until 31
December 2012, was 810 days (Interquartile range
[IQR]: 489–1093). For those with a single recurrent
event (36 patients), the median time from index
hospitalization to the first recurrent event was 278 days
(IQR: 159–522). Of the 405 patients, 359 (88.6 %) pa-
tients did not experience any recurrent event; 36 (8.9 %)
patients experienced a single recurrent event, and 10
(2.5 %) patients experienced ≥ 2 recurrent events. The
three groups were similar in gender, age, health insur-
ance status, smoking status, having dyslipidaemia, having
a family history of premature atherosclerosis, having a
previous history of chronic stable angina, stroke, and
Fig. 1 Index date, study period, and recurrent cardiovascular events
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peripheral vascular disease, having a history of CABG
and carotid intervention, and current medication use.
They also were similar in most of the laboratory findings
except for serum creatinine and eGFR. Characteristics
that differed among groups were diagnosis at discharge,
diabetes mellitus, hypertension, chronic kidney disease,
previous histories of MI or UA, previous histories of per-
cutaneous coronary intervention (PCI), undergoing PCI
during admission, current medication with diabetic
drugs and calcium channel blocker (CCB) (Table 1). Of
those who had a recurrent cardiovascular event, nonfatal
ACS was the most common; ten patients died; ten pa-
tients had multiple recurrent cardiovascular events; one
patient had seven cardiovascular events (all nonfatal
ACS) (Table 2).
The univariable ordinal logistic regression showed that
the significant clinical indicators associated with recur-
rent cardiovascular outcomes were achieving LDL-C
goal of < 70 mg/dL, revascularization, eGFR <60 mL/min/
1.73 m2, increased age, hypertension, use of angiotensin-
converting enzyme inhibitors (ACEI/ARB) (Table 3). With
multivariable ordinal logistic regression, four clinical fac-
tors (2 protective factors and 2 risk factors) associated
with recurrent cardiovascular events were achieving LDL-
C goal of < 70 mg/dL (Adjusted OR = 0.43; 95 % CI =
0.27–0.69, p-value < 0.001), undergoing revascularization
during admission (Adjusted OR = 0.44; 95 % CI = 0.24–
0.81, p-value = 0.009), being male (Adjusted OR = 1.85;
95 % CI = 1.29–2.66, p-value = 0.001), and eGFR < 60 mL/
min/1.73 m2 (Adjusted OR = 2.46; 95 % CI = 2.21–2.75, p-
value < 0.001) (Table 3). In our study, there were five non-
cardiovascular deaths; nevertheless, the results of clinical
indicators on recurrent cardiovascular events were con-
sistent when using cardiovascular death instead of all-
cause death. In addition, ACEI/ARB was found to be a
protective factor for recurrent events (the data not
shown).
Discussion
In our study, multiple recurrent cardiovascular events
occurred in 2.5 % of ACS patients, which are in line with
previous studies that 1–9 % of patients had multiple re-
current cardiovascular events. Our study to investigate
the clinical factors that were associated with recurrent
cardiovascular events identified two protective factors –
achieving LDL-C goal of less than 70 mg/dL, and under-
going revascularization (either PCI or CABG) during ad-
mission. The study also found two risk factors for
further events – male gender and decreased eGFR.
Achieving LDL-C goal of less than 70 mg/dL
Our finding shows that patients with ACS who achieve
the LDL-C goal of less than 70 mg/dL have fewer recurrent
cardiovascular events compared to those not achieving
goal. To our knowledge, there is no other study that inves-
tigates the association between LDL-C goal achievement
and recurrent cardiovascular events. However, some stud-
ies [16–18], including our former study [19], demonstrated
that lowering LDL-C to less than 70 mg/dL resulted in re-
ducing the incidence of cardiovascular events. Our previ-
ous study revealed that ACS patients treated with statins
who achieved an LDL-C goal of <70 mg/dL had signifi-
cantly fewer composite cardiovascular outcomes [19].
Similarly, the results from the two post-hoc analyses from
the PROVE IT-TIMI 22 RTC (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In Myo-
cardial Infarction 22) [17, 18] showed that ACS patients
with the lower LDL-C values (≤40 mg/dL and >40 to
60 mg/dL groups) had a reduction in cardiac events (death,
MI, stroke, recurrent ischemia, revascularization) when
compared with the reference group (>80 to 100 mg/dL)
[17]. The same study found that elderly patients with ACS
who attained LDL-C levels < 70 mg/dL had a 40 % relative
lower risk of acute cardiac clinical events of death, MI, or
UA requiring rehospitalisation [18].
Further, a recently released result of a RCT study, the
IMProved Reduction of Outcomes: Vytorin Efficacy
International Trial (IMPROVE-IT) [20–22], conducted
over 9 years on 18,144 patients with post-ACS from 39
countries, showed that an LDL-C less than 60 mg/dL is
associated with a reduction in cardiovascular events.
The primary end point of that study was a composite of
cardiovascular death, MI, unstable angina requiring
rehospitalisation, coronary revascularization, or stroke.
The primary endpoint in the ezetimibe plus simvastatin
group, with LDL-C of about 53 mg/dL after 1 year of
follow-up, was decreased by 6.4 % over 7 years when
compared with the simvastatin (40 mg) only group, with
LDL-C of about 69 mg/dL (p = 0.016).
Many guidelines, such as the ESC/EAS Guidelines for
the management of dyslipidemias [13], and the 2014 Na-
tional Lipid Association [23], recommend an LDL-C
goal of less than 70 mg/dL as a target for therapy in
ACS patients. Recently, some guidelines – 2013 ACC/
AHA on cholesterol management [24] and the NICE
guidelines on lipid modification [25] – does not recom-
mend the LDL-C goal because they found no evidence
from RCTs studies to confirm an association between
treating to the LDL-C target and cardiovascular events
or mortality. As a result, the treating to target approach
has been debatable in lipid management for some physi-
cians. Our finding supports that treating to an LDL-C
target of less than 70 mg/dL is beneficial because pa-
tients who do not achieve this goal are more likely to
have subsequent cardiovascular events. This suggests
that physicians should discuss with patients the import-
ance of getting their LDL-C goal below 70 mg/dL to re-
duce their risk of further cardiovascular events.
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Table 1 Baseline characteristics of acute coronary syndrome patients with no cardiovascular events, a single event, or multiple
events (n = 405)
Characteristics Recurrent cardiovascular events p-value for trend
0 1 ≥2
(n = 359) (n = 36) (n = 10)
Gender
Male 215 (60.0) 24 (66.7) 6 (60.0) 0.600
Age, (year) 64.5 ± 11.5 68.1 ± 11.7 66.7 ± 11.6 0.128
Health insurance
Universal coverage scheme 201 (56.0) 19 (52.8) 5(50.0) 0.630
Civil servant medical benefit scheme 139 (38.7) 16 (44.4) 4 (40.0)
Social security scheme 15 (4.2) 1 (2.8) 1 (10.0)
Self- pay 4 (1.1) 0 (0.0) 0 (0.0)
Smoking
Non smoker 208 (57.9) 23 (63.9) 8 (80.0) 0.204
Ex-smoker 67 (18.7) 6 (16.7) 0 (0.0)
Current smoker 84 (23.4) 7 (19.4) 2 (20.0)
Diagnosis at discharge
Unstable angina 66 (18.4) 5 (13.9) 7 (70.0) 0.001
NSTEMI 90 (25.1) 16 (44.4) 2 (20.0)
STEMI 203 (56.6) 15 (41.7) 1 (10.0)
Atherosclerotic risk factors
Diabetes mellitus 97 (27.0) 15 (41.7) 5 (50.0) 0.019
Hypertension 215 (59.9) 29 (80.6) 7 (70.0) 0.039
Chronic kidney disease 37 (10.3) 12 (33.3) 2 (20.0) 0.001
Dyslipidemia 141 (39.3) 17 (47.2) 6 (60.0) 0.119
Family history of premature atherosclerosis 7 (1.9) 0 (0.0) 0 (0.0) 0.369
Previous history of cardiovascular events
Chronic stable angina 30 (8.4) 2 (5.6) 3 (30.0) 0.174
Myocardial infarction or unstable angina 71 (19.8) 11 (30.6) 5 (50.0) 0.008
Stroke (Ischemic) 22(6.1) 1 (2.8) 1 (10.0) 0.870
Peripheral vascular disease 1 (0.3) 0 (0.0) 0 (0.0) 0.736
Previous history of cardiovascular intervention
PCI 19 (5.3) 4 (11.1) 3 (30.0) 0.002
CABG 17 (4.7) 0 (0.0) 3 (30.0) 0.071
Revascularization of peripheral vascular disease 1 (0.3) 0 (0.0) 0 (0.0) 0.736
Carotid intervention 2 (0.6) 0 (0.0) 0 (0.0) 0.633
Treatment during admission
PCI 151 (42.1) 7 (19.4) 1 (10.0) 0.001
CABG 4 (1.1) 1 (2.8) 0 (0.0) 0.735
Thrombolytic indicated 43 (12.0) 6 (16.7) 1 (10.0) 0.690
Medications
Lipid lowering drugs (non-statins) 9 (2.5) 1 (2.8) 1 (10.0) 0.271
Antiplatelet/Anticoagulant drugs 350 (97.5) 35 (97.2) 10 (100.0) 0.766
Beta-blockers 296 (82.5) 31 (86.1) 9 (90.0) 0.414
ACEI/ARB 235 (65.5) 18 (50.0) 5 (50.0) 0.054
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Revascularization
Our findings show that undergoing revascularization, ei-
ther with PCI or CABG, is associated with fewer subse-
quent cardiovascular events. To our knowledge, no
studies have been conducted to assess the impact of revas-
cularization on recurrent cardiovascular events. Neverthe-
less, previous studies [26–31] showed improvement in the
clinical outcomes of ACS patients who underwent revas-
cularization procedures during hospitalization. For ex-
ample, a study conducted by Held et al. revealed that
revascularization within 14 days of hospital admission for
ACS was associated with a significant 30 % reduction in 1-
year mortality [26]. The results of the Canadian ACS
Registry showed that in-hospital revascularization was as-
sociated with better 1-year survival only among patients
with high-risk non–ST- elevation acute coronary syn-
drome [27]. Vanasse et al. demonstrated that patients with
myocardial infarction who underwent revascularization
had a better 2-year cardiovascular survival rate compared
to patients without revascularization, regardless of
pharmacological treatments [31].
It has to be noted that there was higher prevalence of
revascularization in this study than in the two registries
of ACS patients in Thailand, possibly because this study
was conducted in a University hospital where all patients
were managed by cardiologists, while the two Thai ACS
registries reported on a variety of hospitals with different
capabilities [3, 4]. Also, the proportion of ACS patients
that underwent revascularization is higher than that in a
study in Sri Lanka where no patients presenting with
STEMI underwent PCI or CABG [32].
Male gender
The association between gender and mortality among
the patients with cardiovascular disease is inconclusive
[33–37]. In our study more males died than females; of
ten deaths, six were males. However, this total is too low
for generalizations. We also found that males were more
likely to have recurrent cardiovascular events; this is
consistent with a study by Wilson et al. that being male
was a significant predictor of recurrent cardiovascular
events [34]. However, Movahed et al. found a higher
mortality rate among women undergoing percutaneous
Table 1 Baseline characteristics of acute coronary syndrome patients with no cardiovascular events, a single event, or multiple
events (n = 405) (Continued)
CCB 71 (19.8) 7 (19.4) 7 (70.0) 0.006
Diuretics 100 (27.9) 14 (38.9) 1 (10.0) 0.979
Diabetic drugs 53 (14.8) 8 (22.2) 4 (40.0) 0.021
Baseline laboratory results
Serum creatinine (mg/dL) 1.4 ± 1.8 1.8 ± 1.1 1.3 ± 0.4 0.003
eGFR (mL/min/1.73 m2) 62.7 ± 25.7 46.3 ± 23.0 58.5 ± 21.8 0.004
ALT (U/L) 35.4 ± 45.5 41.5 ± 88.8 26.6 ± 10.0 0.142
Fasting blood glucose (mg/dL)a 135.1 ± 75.3 134.1 ± 47.7 164.4 ± 70.5 0.230
Total cholesterol (mg/dL) 181.1 ± 50.4 185.4 ± 43.5 169.8 ± 46.8 0.757
Triglyceride (mg/dL)b 137.0 ± 81.2 158.7 ± 89.5 196.4 ± 153.9 0.086
High density lipoprotein (mg/dL)c 40.4 ± 11.7 38.0 ± 7.5 34.8 ± 9.7 0.168
Low density lipoprotein (mg/dL) 112.6 ± 41.9 114.0 ± 37.9 92.3 ± 29.6 0.300
Median follow-up time (day)d 808 (490–1,073) 782 (306–1,146) 1,088 (674–1,239) 0.609
Abbreviations: LDL-C, low-density lipoprotein cholesterol; mg/dL, milligrams per deciliter; NSTEMI, non –ST segment elevation myocardial infarction; STEMI, ST
segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; ACEI/ARB, angiotensin-converting
enzyme inhibitors/angiotensin II receptor blockers; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase;
U/L, units/liter
Notes: Numbers are n (%) or mean ± standard deviation (SD) or median (Interquartile range); the data were missing for some variables, afasting blood glucose,
n = 343, 35, 9; btriglyceride, n = 335, 32, 5; c high density lipoprotein, n = 335, 32, 5; d time form index hospitalization to last medical contact
Table 2 Summary of recurrent cardiovascular events
Recurrent events (n = 46) Patients with event





Multiple recurrent events (n = 10)




Three recurrent events (all nonfatal ACS) 2
Four recurrent events (all nonfatal ACS) 1
Seven recurrent events (all nonfatal ACS) 1
Abbreviations: MI, myocardial infarction; ACS, acute coronary syndrome
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coronary intervention in comparison to men [35].
Singh et al. reported no significant differences between
men and women patients after PCI in short-term (30-
day mortality) or long-term mortality, after accounting
for risk factors [36]. Similarly, a study by D’Ascenzo et
al. found similar long-term major adverse cardiac
events between the female and male patients undergo-
ing PCI [33].
Decreased eGFR
Elevated serum creatinine and decreased eGFR suggest
impaired renal function, with eGFR being a more reli-
able indicator [1]. Studies showed that increased serum
creatinine or decreased eGFR was associated with major
adverse cardiac events [38–46]. Our finding adds to that
knowledge i.e. renal dysfunction, based on eGFR <
60 mL/min/1.73 m2, is associated with recurrent cardio-
vascular events. This observation is in line with previous
studies that renal dysfunction was found to predict the
likelihood of recurrent cardiovascular disease [10, 47].
Limitations
Due to the limitations of this study, the results should
be interpreted with caution. The first limitation is re-
lated to the nature of retrospective study design, in that
residual and/or unknown confounding factors could exit,
and some data were unavailable. For example, the time
from hospital admission of the ACS patients to the as-
sessment of LDL-C goal attainment varied from 2 weeks
to one year, depending on the availability of the patients’
lipid profiles on the first follow-up visit. As per the ESC/
EAS Guidelines for the management of dyslipidaemias
[13], patients’ lipids should be tested 4–12 weeks after
starting lipid-lowering treatment. In our study, few
patients (25, 6.2 %) had an LDL-C measurement before
4 weeks. Second, all patients included in the study had a
very high cardiovascular risk (ACS patients), so the find-
ings may not apply to patients with less severe disease.
In addition, all patients were treated by cardiologists at a
University hospital where the level of care exceeds that
in lower level hospitals. Third, the number of patients
with the occurrence of recurrent events was also very
low (36 patients or 8.9 % with single recurrent event,
and 10 patients or 2.5 % with multiple recurrent events),
so that larger scale studies are required before the rela-
tionships found here can be generalized. Fourth, al-
though some biomarkers have been shown to be
independent prognostic markers for morbidity and mor-
tality in ACS patients, e.g., B-type natriuretic peptide
and high-sensitivity C-reactive protein [48, 49], these
biomarkers have not been routinely measured in clinical
practice in our setting. Biomarkers therefore were not
included as potential clinical indicators for recurrent
events in our study.
However, only a few studies have assessed the relation-
ship between LDL-C goal attainment and cardiovascular
events, and even fewer looked at subsequent cardiovas-
cular events in a real-world setting; our study provides
information about the factors associated with recurrent
cardiovascular events in ACS patients in real world prac-
tice based on information collected as part of routine
clinical practice. Our findings will be of use to physicians
to identify ACS patients at higher risk of recurrent car-
diovascular events who should be intensively followed
up to prevent subsequent cardiac events, namely those
ACS patients who do not achieve the LDL-C goal of <
70 mg/dL, did not undergoing revascularization, are
male, and have decreased eGFR.
Table 3 Univariable and multivariable analysis of clinical indicators for recurrent cardiovascular events (n = 405)
Clinical indicators OR (95 % CI) p-value Multivariable OR (95 % CI) p-value
LDL-C goal attainment
LDL-C≥ 100 mg/dL 1.00 1.00
LDL-C 70–99 mg/dL 0.75 (0.36–1.58) 0.448 0.67 (0.35–1.30) 0.240
LDL-C < 70 mg/dL 0.55 (0.33–0.91) 0.019 0.43 (0.27–0.69) <0.001
Revascularization 0.32 (0.17–0.63) 0.001 0.44 (0.24–0.81) 0.009
eGFR < 60 mL/min/1.73 m2 3.24 (2.74–3.82) <0.001 2.46 (2.21–2.75) <0.001
Male gender 1.25 (0.79–1.96) 0.337 1.85 (1.29–2.66) 0.001
Age (year) 1.03 (1.01–1.04) <0.001 1.00 (0.99–1.03) 0.258
Hypertension 2.39 (1.20–4.73) 0.013 1.66 (0.70–3.95) 0.249
ACEI/ARB 0.53 (0.35–0.81) 0.003 0.72 (0.49–1.06) 0.101
Diabetes mellitus 2.09 (0.67–6.50) 0.202 1.56 (0.52–4.73) 0.428
Follow-up time (day)a 1.00 (1.00–1.00) 0.908 1.00 (1.00–1.00) 0.890
Abbreviations: OR, odds ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; mg/dL, milligrams per deciliter; eGFR, estimated glomerular filtration
rate; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers
Note: atime from index hospitalization to the last medical contact
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Conclusion
In conclusion, this study of routine clinical practice in
ACS patients found that achieving an LDL-C goal of less
than 70 mg/dL and undergoing revascularization are
protective factors, whereas male gender and an eGFR
less than 60 mL/min/1.73 m2are risk factors for recur-
rent cardiovascular events. These clinical indicators
should be used for routine-monitoring of patients to
prevent recurrent cardiovascular events in ACS patients.
Abbreviations
ACS: Acute coronary syndrome; GRACE: Global Registry of Acute Coronary
Events; TACS: Thai Acute Coronary Syndrome; TRACS: Thai Registry of Acute
Coronary Syndrome; ICD-10: International Classification of Diseases, 10th
Revision; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density
lipoprotein cholesterol; IMPROVE-IT: IMProved Reduction of Outcomes:
Vytorin Efficacy International Trial; UA: Unstable angina; NSTEMI: Non-ST
segment elevation myocardial infarction; STEMI: ST segment elevation
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